Elbit Systems benefits from sustained global defense spending, record backlog, and improving profitability, but its elevated valuation and geopolitical exposure limit the margin of safety for new investors.
Hold-rated reports
904 tickers rated HoldXPeng combines expanding intelligent EV sales, overseas growth and physical AI optionality with an improving path toward profitability, but fierce competition and volatile cash flow remain major obstacles to durable shareholder returns.
Hudbay Minerals offers diversified copper-gold cash generation and substantial U.S. copper growth potential, but commodity volatility, heavy development spending, and acquisition-related dilution constrain its margin of safety.
CAE benefits from durable aviation training demand and improving defense profitability, but capital-intensive operations, weak Civil margins, and demanding earnings expectations limit near-term investment upside.
Liquidia's rapid YUTREPIA commercialization and high-margin PAH franchise offer substantial earnings potential, but product concentration, litigation settlement costs, and growth normalization limit near-term upside.
National Health Investors offers recurring healthcare property income and demographic-driven senior housing growth, but SHOP execution challenges and weaker normalized FFO per share constrain near-term upside.
Csquare offers accelerating growth in contracted data center infrastructure demand and improving adjusted operating margins, but substantial leverage, negative free cash flow and future share supply constrain the investment case.
JBS offers a diversified global protein platform with meaningful earnings recovery potential, but elevated leverage, weak cash conversion, and volatile livestock-processing margins constrain near-term upside.
Hims & Hers offers long-term growth through personalized digital healthcare and international expansion, but deteriorating gross margins, weak cash conversion, and pharmaceutical dependence threaten sustainable shareholder returns.
Protagonist Therapeutics has transformed two innovative peptide drugs into approved royalty-generating franchises with substantial pipeline upside, but milestone-heavy earnings, commercialization uncertainty, and dilution constrain the investment case.
Ameren's regulated utility franchise and contracted electricity-demand growth support durable earnings expansion, but heavy capital spending, shareholder dilution and regulatory uncertainty limit the stock's margin of safety.
People's MGM investment, established publishing brands, and restructuring-led cost savings create an asset-backed value opportunity, although AI-driven traffic disruption and concentrated investment exposure limit conviction.